Home Your basket
• Perilymphatic Gusher as a...
   Price 10.50 €
• Solitary fibrous tumour o...
   Price 8.50 €
• Study of the predictive v...
   Price 10.50 €
• Orbital apex syndrome fol...
   Price 10.50 €
• Role of diffusion weighte...
   Price 10.50 €
• Laryngeal sarcoidosis: Ca...
   Price 5.50 €
• Failure rate and revision...
   Price 10.50 €
• Reports to the General As...
   Price 10.50 €
• Contribution of clinical ...
   Price 14.00 €
• Voice handicap evaluation...
   Price 10.50 €
• Complicated fungal sinusi...
   Price 8.50 €
• Dehiscence of the anterio...
   Price 8.50 €
• Chronic laryngitis...
   Price 8.50 €
• Complete branchial cleft ...
   Price 5.50 €
• Fistula of the fourth bra...
   Price 5.50 €
• Spontaneous cholesteatoma...
   Price 8.50 €
• A survey of current wound...
   Price 5.50 €
• Laryngeal tuberculosis: A...
   Price 5.50 €
• The “Deglutition Handicap...
   Price 10.50 €
• Transsexualism: From diag...
   Price 10.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Enlarged marginal incisio...
   Price 10.50 €
• Notes on voice and speech...
   Price 8.50 €
• TRT: Results after one ye...
   Price 10.50 €
• Invasive cholesteatoma in...
   Price 10.50 €
• Ganglioneuroma in saharan...
   Price 10.00 €
• Middle ear osteoma: A rar...
   Price 8.50 €
• Medical rhinoplasty: Rati...
   Price 10.00 €
• Pleomorphic adenoma of th...
   Price 12.00 €
• Ethmoidal metastasis reve...
   Price 8.50 €
• The use of speech therapy...
   Price 10.50 €
• Endoscopic endonasal surg...
   Price 8.50 €
• Long-term results of faci...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Correlation between the r...
   Price 12.50 €
• Assessing efficacy of voi...
   Price 5.50 €
• Cephalic vein access for ...
   Price 10.50 €
• Neck masses in children: ...
   Price 14.00 €
• Endoscopic resection of s...
   Price 10.50 €
• Alternative clinical mana...
   Price 10.50 €
• Non-functioning parathyro...
   Price 5.50 €
• Adenoid cystic carcinoma ...
   Price 10.50 €
• Esthesioneuroblastoma....
   Price 5.50 €
• Lateral semicircular cana...
   Price 10.50 €
• MIF in Head and Neck canc...
   Price 10.50 €
• Thyroid papillary microca...
   Price 10.50 €
• Adenocarcinoma of the eth...
   Price 8.50 €
• Deafness in adults. Study...
   Price 10.50 €
• Ossiculoplasty with hydro...
   Price 10.50 €
• The value of the operatin...
   Price 10.50 €
• Pseudoaneurysm of the int...
   Price 5.50 €
• Somatic tinnitus (review)...
   Price 12.50 €
• Transverse maxillary defi...
   Price 8.50 €
• Tuberculosis of the parot...
   Price 5.50 €
• Neuroplasticity in the au...
   Price 10.50 €
• Blepharoplasty and upper ...
   Price 10.50 €
• The pedicled musculo-cuta...
   Price 8.50 €
• Periphery, central and ps...
   Price 10.50 €
• Parathyroid carcinoma: di...
   Price 5.50 €
• Teratoma of the parotid g...
   Price 5.50 €
• Multi-factorial analysis ...
   Price 10.50 €
• Temporary loss of visual ...
   Price 8.50 €
• Bone-Anchored Hearing Aid...
   Price 10.50 €
• Delayed facial palsy afte...
   Price 8.50 €
• Comparative results of ty...
   Price 10.50 €
• Signs of upper Airways di...
   Price 10.50 €
• Detection and role of hum...
   Price 14.00 €
• Personality study in prof...
   Price 5.50 €
• What is the effect of diz...
   Price 10.50 €
• Interest of MIBI scintigr...
   Price 10.50 €
• Vestibular neuritis: Eval...
   Price 14.00 €
• International Conference ...
   Price 5.50 €
• The relationship between ...
   Price 5.50 €
• Side-to-end hypoglossal-f...
   Price 10.50 €
• Otoplasty for prominent e...
   Price 8.50 €
• Results of alginate and h...
   Price 10.50 €

Total Order 701.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE